Allurion Technologies (ALUR) AI Stock Analysis

• Market Cap: $15.14M
• Dividend Yield: N/A
• Average Volume (3M): 48.50K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.36
• Revenue Growth: -58.15%
• EPS Growth: 93.84%
• Country: US
• Employees: 134
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -1.28
• Shares Outstanding: 7,762,681
• 10 Day Avg. Volume: 67,416
• 30 Day Avg. Volume: 48,497
• PEG Ratio: 0.01
• Price to Book (P/B): -0.31
• Price to Sales (P/S): 0.75
• P/FCF Ratio: -0.56
• Enterprise Value/Market Cap: 2.35
• Enterprise Value/Revenue: 1.78
• Enterprise Value/Gross Profit: 2.89
• Enterprise Value/Ebitda: -1.19
• 1Y Price Target: $6.00
• Price Target Upside: 227.87% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 42 Neutral
• Price Target: $2.00 ▲(9.29% Upside)

Allurion Technologies' overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and persistent losses. The technical analysis supports a bearish outlook, while valuation metrics highlight ongoing profitability issues. Although the earnings call suggests a promising strategic pivot, significant short-term challenges and disruptions remain.

Positive Factors

Strategic Pivot

The strategic pivot to combine the Allurion Program with GLP-1 therapy shows promise for future growth, enhancing product effectiveness and market appeal.

R&D and Clinical Pipeline Advances

Advancements in R&D and clinical pipeline, including a novel product development, strengthen Allurion's competitive position and future product offerings.

Reduction in Operating Expenses

Significant reduction in operating expenses improves financial efficiency, potentially leading to better profitability and cash flow management.

Negative Factors

Revenue Decline

The substantial revenue decline indicates challenges in market penetration and sales execution, which may impact long-term growth prospects.

High Leverage and Negative Equity

High leverage and negative equity pose risks to financial stability, limiting the company's ability to invest in growth and withstand economic downturns.

Negative Cash Flow

Negative cash flows highlight liquidity issues, indicating reliance on external financing, which is unsustainable without improved financial performance.

Allurion Technologies Business Overview & Revenue Model

Company Description

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company is headquartered in Natick, Massachusetts.

How the Company Makes Money

Allurion Technologies generates revenue through the sale of its medical devices, particularly the Allurion Balloon and associated services. The company typically sells its products directly to healthcare providers, hospitals, and clinics, which then offer these solutions to patients seeking weight loss options. Additionally, Allurion has developed partnerships with healthcare institutions and professionals to enhance the distribution of its products and services, creating a network that expands its market reach. The company may also generate income through subscription services for ongoing support and coaching, contributing to a recurring revenue model. Furthermore, Allurion's collaborations with insurance companies can facilitate reimbursement for its products, enhancing access to patients and driving sales.

Allurion Technologies Financial Statement Overview

Summary

Allurion Technologies faces significant financial challenges, including declining revenue, persistent losses, high leverage, and negative cash flows. These issues indicate a need for strategic changes to stabilize and improve financial health.

Income Statement

Allurion Technologies has experienced significant revenue fluctuations, with a notable decline from 2022 to 2023. The company faces negative profit margins, including a negative gross profit margin in 2024, and sustained losses in net income, EBIT, and EBITDA, indicating ongoing challenges in achieving profitability.

Balance Sheet

The balance sheet reveals a concerning financial structure, with negative stockholders' equity and high leverage as indicated by a high debt-to-equity ratio. The equity ratio is negative, reflecting a risk of insolvency, compounded by the decline in assets and insufficient equity to cover liabilities.

Cash Flow

Cash flow analysis shows persistently negative operating and free cash flows, signaling liquidity issues. The company has relied heavily on financing activities to fund operations, which is unsustainable in the long term without improved financial performance.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	19.92M	32.11M	53.47M	64.21M	38.24M	0.00
Gross Profit	12.30M	21.50M	41.50M	50.73M	29.19M	0.00
EBITDA	-29.83M	-22.17M	-69.03M	-32.28M	-8.01M	-5.17K
Net Income	-40.41M	-26.15M	-80.61M	-37.74M	-12.39M	-5.17K
Balance Sheet
Total Assets	28.17M	32.81M	71.71M	51.37M	39.35M	329.96K
Cash, Cash Equivalents and Short-Term Investments	12.72M	15.38M	38.04M	7.68M	25.84M	47.09K
Total Debt	30.52M	37.92M	41.86M	59.53M	26.14M	170.00K
Total Liabilities	92.14M	110.79M	142.20M	122.81M	73.64M	310.13K
Stockholders Equity	-63.98M	-77.98M	-70.49M	-71.44M	-34.28M	19.83K
Cash Flow
Free Cash Flow	-41.89M	-42.91M	-65.59M	-48.53M	-15.24M	―
Operating Cash Flow	-41.82M	-42.30M	-63.98M	-46.98M	-14.33M	―
Investing Cash Flow	-72.00K	-611.00K	-1.61M	-1.55M	-912.00K	0.00
Financing Cash Flow	35.31M	20.21M	95.99M	30.54M	28.95M	47.13K

Allurion Technologies Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.83
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALUR, the sentiment is Negative. The current price of 1.83 is below the 20-day moving average (MA) of 1.99, below the 50-day MA of 2.08, and below the 200-day MA of 2.85, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 34.10 is Neutral, neither overbought nor oversold. The STOCH value of 10.82 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALUR.

Allurion Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NVNO	―	$13.42M	-0.55	-64.55%	―	―	15.60%
CODX	―	$28.16M	-0.42	-63.40%	―	-91.14%	9.47%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IRIX	―	$18.01M	-3.24	-105.72%	―	0.09%	51.09%
ALUR	―	$15.14M	-0.81	―	―	-58.15%	93.84%
SINT	―	$12.49M	-0.33	-195.48%	―	-40.47%	96.14%
XAIR	―	$15.87M	-0.17	-323.27%	―	168.20%	63.41%

Allurion Technologies Corporate Events

Allurion Technologies’ Earnings Call: Strategic Shift Amid Revenue Challenges

Allurion Technologies, Inc. Navigates Strategic Transition Amidst Revenue Challenges

Allurion Technologies Delays Q2 2025 Financial Filing

Allurion Technologies, Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending June 30, 2025. The delay is primarily due to the need to restate previous financial statements because of errors in accounting related to the fair value of its revenue interest financing agreement and convertible senior secured notes. The company aims to file the report within the five-day extension period allowed by regulations but cannot guarantee this timeline. Preliminary financial results indicate a significant decrease in revenue and gross profit compared to the same period last year, with a slight reduction in operational losses. Allurion Technologies is actively working on compliance and the notification was signed by Chief Legal Officer Brendan M. Gibbons.

The most recent analyst rating on (ALUR) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Allurion Technologies stock, see the ALUR Stock Forecast page.

Allurion Technologies Shifts Strategy Amid Q2 Earnings

Allurion Technologies, Inc. is a company specializing in metabolically healthy weight loss solutions, primarily known for its innovative swallowable gastric balloon and virtual care suite designed to aid in weight management. Operating in the healthcare sector, Allurion is recognized for its unique approach to obesity management, which emphasizes maintaining muscle mass while achieving weight loss.

Allurion Technologies Reports Q2 Results and Strategic Pivot

On August 13, 2025, Allurion Technologies announced its second quarter financial results, revealing a strategic pivot towards low-dose GLP-1 combination therapy and U.S. market entry. The company reported a revenue of $3.4 million for the quarter, reflecting a decrease due to distributor transitions and reduced sales in certain markets. Despite this, Allurion is optimistic about long-term growth through new strategic partnerships and a focus on next-generation R&D, aiming to establish a new standard of care in obesity management.

The most recent analyst rating on (ALUR) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Allurion Technologies stock, see the ALUR Stock Forecast page.

Allurion Technologies Announces Strategic Restructuring Plan

On August 5, 2025, Allurion Technologies announced a strategic restructuring plan to focus on low-dose GLP-1 combination therapy, muscle mass maintenance, and U.S. market entry. This plan involves a significant workforce reduction and aims to enhance distribution and R&D capabilities, including a potential joint development of a novel GLP-1 drug-eluting balloon. The company is transitioning to distribution partners with access to physician networks and has observed growth in clinics adopting the combination therapy. Despite short-term disruptions, Allurion expects long-term growth and improved financial performance.

The most recent analyst rating on (ALUR) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Allurion Technologies stock, see the ALUR Stock Forecast page.